J Drugs Dermatol. 2023 Aug 1;22(8):835-837. doi: 10.36849/jdd.7134.
Conflicting evidence exists regarding the role of race in access to biologics for patients with psoriasis.
To compare biologic use among adult and pediatric United States psoriasis patients of different racial backgrounds.
Population-based study of US psoriasis patients using the 2003 to 2018 Medical Expenditure Panel Survey (MEPS).
Among 31,525,500 adults and children with psoriasis (weighted), 3,026,578 (9.6%) were on biologics. Among psoriasis patients, 27,464,864 (87.1%) self-identified as white, 2,033,802 (6.5%) self-identified as Black, 1,173,435 (3.7%) self-identified as Asian or Pacific Islander, and 853,399 (2.7%) self-identified as other races. Among those on biologics, 2,778,239 (91.8%) self-identified as white, 84,971 (2.8%) identified as Black, 89,452 (3.0%) self-identified as Asian or Pacific Islander, and 73,917 (2.4%) self-identified as other races. Multivariate logistic regression revealed no significant differences in biologic access between whites and non-whites after adjusting for sociodemographic factors including insurance status (OR for Blacks: 0.347 [0.118, 1.021], P=0.055; OR for Asians: 0.616 [0.240, 1.579], P=0.311; OR for other races: 0.850 [0.216, 3.336], P=0.814.
The results of this study suggest that race alone is not independently associated with access to biologics among adult US psoriasis patients. Additional studies are necessary to evaluate factors independently associated with biologics access among adults and children with psoriasis in the US. J Drugs Dermatol. 2023;22(8):835-837. doi:10.36849/JDD.7134 Reddy R, Khan S, Yee D, et al. No racial differences found in access to biologics: a population-based study of psoriasis patients in the United States. .
种族在银屑病患者获得生物制剂方面的作用存在相互矛盾的证据。
比较不同种族背景的美国银屑病成年和儿童患者使用生物制剂的情况。
使用 2003 年至 2018 年医疗支出调查（MEPS）对美国银屑病患者进行基于人群的研究。
在 31525500 名患有银屑病的成年人和儿童中（加权），有 3026578 人（9.6%）使用生物制剂。在银屑病患者中，27464864 人（87.1%）自我认定为白人，2033802 人（6.5%）自我认定为黑人，1173435 人（3.7%）自我认定为亚洲或太平洋岛民，853399 人（2.7%）自我认定为其他种族。在使用生物制剂的人群中，2778239 人（91.8%）自我认定为白人，84971 人（2.8%）认定为黑人，89452 人（3.0%）自我认定为亚洲或太平洋岛民，73917 人（2.4%）自我认定为其他种族。多变量逻辑回归显示，在调整了包括保险状况在内的社会人口因素后，白人患者和非白人患者在生物制剂的使用上没有显著差异（黑人的 OR：0.347 [0.118, 1.021]，P=0.055；亚洲人的 OR：0.616 [0.240, 1.579]，P=0.311；其他种族的 OR：0.850 [0.216, 3.336]，P=0.814）。
本研究结果表明，种族本身并不是美国成年银屑病患者获得生物制剂的独立相关因素。需要进一步研究评估美国银屑病成年和儿童患者获得生物制剂的独立相关因素。J 皮肤病学杂志。2023；22（8）：835-837。doi:10.36849/JDD.7134 Reddy R，Khan S，Yee D，et al. 在美国，没有发现种族差异影响生物制剂的可及性：一项基于人群的银屑病患者研究。
